BioMarin Pharmaceutical (BMRN) vs Elanco Animal Health (ELAN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Elanco Animal Health (ELAN) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 9.3% versus a gain of 0.9%. Over five years, BMRN leads with a -27.3% price change compared with -31.3% for ELAN. Elanco Animal Health is the larger company by market cap ($11.26 billion vs $10.63 billion), about 1.1 times the size, while BioMarin Pharmaceutical is growing revenue faster (+12.9% vs +6.2%).
On valuation, BioMarin Pharmaceutical trades at a lower forward P/E (8.3x vs 17.5x for Elanco Animal Health). BioMarin Pharmaceutical converts more of its revenue into profit, with a net margin of 10.8% versus -4.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRN | ELAN |
|---|---|---|
| Share price | $54.89 | $22.54 |
| Market cap | $10.63B | $11.26B |
| 1-day change | -0.56% | +0.81% |
| YTD return | -7.12% | -1.19% |
| 1-year return | +0.91% | +9.34% |
| 5-year return | -27.26% | -31.28% |
| P/E ratio (TTM) | 148.35 | — |
| Forward P/E | 8.28 | 17.54 |
| EPS (TTM) | $0.37 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.22B | $4.71B |
| Revenue growth (YoY) | +12.87% | +6.22% |
| Net income (latest FY) | $348.90M | $-232.00M |
| Gross margin | 77.73% | 54.99% |
| Operating margin | 12.71% | — |
| Net margin | 10.83% | -4.92% |
| 52-week high | $70.98 | $27.98 |
| 52-week low | $49.26 | $19.40 |
| Distance from 52-week high | -22.67% | -19.44% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +66.92% | +37.53% |
| Average volume | 2.01M | 6.18M |
| Shares outstanding | 193.57M | 499.45M |
| Employees | 3,221 | 9,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BioMarin Pharmaceutical is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -4.9 cents for Elanco Animal Health.
- BioMarin Pharmaceutical grew revenue faster in its latest fiscal year (+12.87% vs +6.22%).
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
About Elanco Animal Health
ELAN stock →Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark.
Health Care · Biotechnology: Pharmaceutical Preparations · 9,400 employees
BMRN vs ELAN FAQ
Which is bigger, BioMarin Pharmaceutical or Elanco Animal Health?
Elanco Animal Health (ELAN) is larger, with a market capitalization of $11.26B compared with $10.63B for BioMarin Pharmaceutical (BMRN).
Which stock has performed better over the past year, BMRN or ELAN?
ELAN returned +9.34% over the past 12 months, compared with +0.91% for BMRN (price return, excluding dividends). Past performance does not predict future results.
Are BioMarin Pharmaceutical and Elanco Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.